Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
Ocular Therapeutix reported a larger quarterly loss while advancing its lead retina drug AXPAXLI through late-stage trials. For the first quarter ended March 31, 2026, total net revenue was $10.8 million, up slightly from $10.7 million a year earlier, driven almost entirely by DEXTENZA product sales.
Research and development spending rose to $66.2 million from $42.9 million as the company funded its Phase 3 SOL-1, SOL-R and HELIOS-3 trials and initiated the SOL-X extension study. Net loss widened to $88.6 million, or $0.40 per share, compared with a $64.1 million loss, or $0.38 per share, in the prior-year quarter.
Cash and cash equivalents were $666.7 million as of March 31, 2026. Ocular believes this balance can fund planned expenses, debt service and capital needs into 2028, including completion of SOL-1, SOL-R topline data, SOL-X, HELIOS-3 and potential HELIOS-2, as well as pre-commercial investment for AXPAXLI.
Ocular Therapeutix is asking stockholders to approve several 2026 annual meeting items, including electing two Class III directors, advisory votes on executive pay and its frequency, and a proposal to increase the 2021 Stock Incentive Plan share pool by 10,000,000 shares.
The proxy highlights 2025 as a transformative year, with expanded Phase 3 programs for AXPAXLI in wet age-related macular degeneration and diabetic retinal disease, a special protocol assessment from the FDA, and $475 million in gross proceeds from an underwritten offering. The company reports sufficient capital, together with anticipated DEXTENZA cash inflows, to fund planned operations, debt service and capital spending into 2028, and notes positive superiority data from the SOL‑1 Phase 3 trial in wet AMD. The board emphasizes a pay-for-performance executive compensation philosophy, heavy use of at-risk equity, independent board oversight, and ongoing stockholder engagement, including outreach to investors holding 31% of shares outstanding after a 74.9% say‑on‑pay support level in 2025.
Ocular Therapeutix director Pravin Dugel reported a bona fide gift of 394,696 shares of Common Stock on April 9, 2026, transferred to his spouse for no consideration. The transfer was recorded as a gift disposition and reflects an internal family reallocation rather than a market sale.
After this transaction, Dugel continues to hold 2,618,326 shares directly. He also has indirect ownership of 394,696 shares held by his spouse and 300,115 shares held by the Pravin Dugel 2024 Irrevocable Trust, indicating a substantial remaining stake in the company.
Ocular Therapeutix Inc: The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned, representing 0% of the class. The amendment explains an internal realignment on January 12, 2026 that led subsidiaries to report holdings separately; Ashley Grim signed on 03/27/2026.
Ocular Therapeutix, Inc. is making investor presentation slides available covering detailed results from its SOL-1 Phase 3 superiority clinical trial of AXPAXLI (also known as OTX-TKI) for treating wet age-related macular degeneration. The slides will be posted on the company’s website Investors section on February 27, 2026, aligned with its presentation at the 49th Macula Society Annual Meeting.
Ocular Therapeutix director and officer Pravin Dugel reported an automatic sale of 20,056 shares of common stock at a weighted average price of $8.28 per share. According to the disclosure, the transaction was carried out under a durable automatic sale instruction adopted on February 21, 2024 to cover tax withholding obligations tied to restricted stock units vesting on February 22, 2026, and is described as not being a discretionary trade.
After this open-market sale, Dugel directly holds 3,013,022 common shares, and an additional 300,115 shares are reported as held indirectly through the Pravin Dugel 2024 Irrevocable Trust.
Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,810 shares of common stock at a weighted average price of $8.28 per share. The shares were sold under a durable automatic sale instruction to cover tax withholding from restricted stock units vesting on February 22, 2026. After this transaction, he directly owns 269,108 shares.
Ocular Therapeutix, Inc.’s Chief Scientific Officer Jeffrey S. Heier reported an automatic sale of 3,057 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.28 per share to cover tax withholding tied to restricted stock units that vested on February 22, 2026.
The transaction was executed under a durable automatic sale instruction adopted on April 9, 2024, meaning it was not a discretionary trade. After this sale, Heier directly held 323,368 shares of Ocular Therapeutix common stock.